What the evidence on RAD 140 teenager exposure records is harm, not safety. A published case report describes a 16-year-old boy who developed myopericarditis, inflammation of cardiac muscle and of the sac around the heart, after his first dose, and its authors add that such side effects can be life-threatening and are poorly characterised.
A mouse study adds that ten weeks of the compound raised mortality risk and frailty (a measured accumulation of age-related health deficits) and in the younger animals blunted the adaptation of skeletal muscle to repeated loading. The warnings aimed at the young rest on something else, on effects described only outside the published studies: suppression of testosterone (the principal androgen made by the testes), erectile dysfunction, and possible harm to growth.
What is RAD 140, and what has it been studied for? RAD140 is a selective androgen receptor modulator (SARM) acting on the androgen receptor, the protein inside cells that responds to androgens, and the 2023 mouse study framed vosilasarm as a possible means of delaying sarcopenia, the age-related loss of skeletal muscle mass. This article sets out what is recorded in the case report, in a drug-safety monograph on the SARM class, in an Australian regulator’s product tests and in the mouse study, and then what is described outside the published studies; the compound’s effects in older adults are covered on other pages of the site.
What are the risks of RAD140 for someone under 21, with figures?
Three records of RAD 140 side effects carry the risks of RAD140 under 21: myopericarditis in a teenage boy after his first dose; cholestatic liver injury (drug-induced damage that impairs bile flow) listed for SARMs as a class; and products that hold less of the compound than their labels state.
Few figures attach to them, and the table below gives all there are: from the case report the boy’s age and the single dose before onset, from the mouse study the dose and length of its treated arm, given to young and adult female mice, in which RAD140 worsened the health of both treated age groups and blunted the adaptive response of the young animals.
Each record has a boundary. The case report covers one patient, the liver monograph covers a whole class of compounds rather than any single age group, and taken at their own level the three records show an event that has occurred once, a pattern of injury linked with the class and the limit of what a label can be trusted to state.
LiverTox links SARMs as a class with cholestatic liver injury in a listing tied to no age group, so one question has the same answer at eighteen as at forty, and its own article gives it: Is RAD 140 liver toxic?
Four published records and their limits
Record
Who or what it covers
What it found
Where it stops
Case report, 2024
One 16-year-old boy
Myopericarditis after the first dose of a product labelled RAD-140
Single case; no rate; cannot exclude other causes
LiverTox monograph
SARMs as a class
Cholestatic liver injury linked with the class
Class entry; no age group and no size of risk
TGA safety alert
Unapproved SARM products on the Australian market
Products significantly under-dosed
Australian market only
Mouse study, 2023
Young and adult female mice; RAD140 5 mg/kg or control for 10 weeks
Higher frailty and mortality risk in both ages; lower adaptive potential in the young
Female mice only; no mechanism given
Heart inflammation in a boy after his first dose
One dose of a product labelled Testolone (RAD-140) preceded the myopericarditis in the published case on RAD-140 and the heart, and the patient was a boy. Myopericarditis joins inflammation of cardiac muscle to inflammation of the pericardium, the thin fibrous sac enclosing the heart, and the authors set his exposure beside a warning that potentially life-threatening side effects remain poorly characterised in his age group.
These drugs are widely abused by physically active young adults; however, the drugs’ side effects, which can be life-threatening, are not well characterized.
The limit of the record follows from its form. A single case shows that myopericarditis occurred after one exposure to a product labelled RAD-140 and not how often the event occurs; the published summary gives no rate, and one case cannot separate the compound from other possible causes, so what the record establishes is an occurrence rather than a frequency. Laboratories that buy UK SARMs from the shop receive the batch data that a label does not give.
What does RAD140 actually do to a teenager’s body, according to evidence?
Beyond the trial data, the effects described for RAD140 in the teenage years are adverse with one exception, an increase in strength.
Erectile dysfunction has been described after a short exposure and, in other accounts, as absent after a longer one, so the duration of exposure alone does not account for the difference, and the effects those accounts describe in the teenage years run as follows:
Libido, the drive towards sexual activity, first raised and then lowered.
Erectile dysfunction within the first weeks.
Constant tiredness at high daily exposure, with testosterone described as absent.
Low testosterone that persists after exposure ends, described alongside the fall in libido, a suppression that outlasts the exposure itself.
Anxiety in a few accounts, often with age raised as a possible factor.
On the other side, an increase in strength.
Most of these accounts concern RAD140 in combination with other compounds, chiefly MK-677 (the growth hormone secretagogue ibutamoren), so the effects they describe cannot be attributed to RAD140 alone; that combination is the first limit of the accounts of RAD140 on Reddit and similar sites, which rarely isolate one compound and so sketch a pattern of suppression and its consequences rather than the effect of any single agent.
Does RAD140 stunt growth or close growth plates in teenagers?
Among the effects described outside the trials, RAD140 may stunt growth and cause early closure of the growth plates, the cartilage zones where long bones lengthen, known in anatomy as epiphyseal plates; only the suppression of endogenous testosterone comes up more often. A still-growing skeleton is accordingly held to be one never to be exposed to the compound, lost height is reported after exposure in the late teens, judged against the family’s greater height and left as an open question, and lifelong incomplete development appears in a few accounts as the cost of exposure before growth has finished.
The opposite possibility is described, outside the trial record, as a widening of the skeletal frame while the growth plates remain open, and the same accounts leave open whether drugs administered after exposure to restart endogenous testosterone production would themselves affect growth; both the stunting and the widening rest on conjecture rather than on measurement.
Closure of the plates is widely understood to be driven by sex hormones, chiefly oestrogen made from testosterone, though androgens also act directly on the cartilage, so early or excess androgen exposure during puberty is held to speed skeletal maturation and close them early, at the cost of final adult height. RAD140 is described as not converting to oestrogen, and the claim that it therefore spares the plates is regarded as speculative, because SARMs suppress endogenous testosterone production and so disturb the hormones governing the pubertal growth spurt, which is why the risk of lost height is considered real.
Does RAD140 affect brain development in teenagers?
RAD140’s effect on brain development in teenagers is generally held to be unknown, because the compound has never been studied in adolescents. The teenage brain is still maturing, testosterone helps to shape that maturation through puberty, and SARMs such as RAD140 suppress endogenous testosterone production, so they are held capable of disturbing the hormonal signals that shape the adolescent brain.
Against that uncertainty, laboratory work in cultured neurons and in rodents has described RAD-140 neuroprotective effects, an early preclinical record that says nothing about safety in the developing brain; the usual view is that a risk to adolescent brain development cannot be ruled out, and that the absence of data gives reason for concern rather than reassurance.
Is it safe to take SARMs like RAD140 at 18?
In descriptions beyond the trials, exposure to SARMs such as RAD140 at eighteen is widely held to be premature rather than safe, and the course most often described is deferral until the hormonal system has settled: at that age endogenous testosterone is already high, so the compound is said to add little in return for what it puts at risk, and the chief long-term danger of early exposure is a lasting loss of endogenous testosterone production.
Uncertainty over what a product actually contains has also been described as a further ground against early exposure, and eighteen as too early whatever the compound, because at that age the endocrine system is held to be still maturing; a minority view accepts exposure only when it is bracketed by RAD 140 blood work, laboratory measurements of circulating hormone levels taken before and after.
Are very low doses of RAD140 any safer at 18?
Beyond the trial data a low dose of RAD140 at eighteen is not described as safe, though a small daily amount over a short period is sometimes described as doing little lasting harm; other accounts set the stage of development against that view and name age rather than amount as the ground for the warning, so the two positions differ in what they hold decisive, one regarding the amount of exposure as the quantity to keep small and the other the maturity of the hormonal system as the deciding condition.
Taken together, in those accounts, the grounds against exposure at eighteen are these:
Endogenous testosterone is already high, so the compound adds little in return.
A lasting loss of endogenous testosterone production is the chief long-term danger.
What a product actually contains is uncertain.
The endocrine system is still maturing at that age.
Suppression of endogenous testosterone is widely described even at small amounts.
In a minority view, exposure is accepted only when bracketed by blood tests taken before and after.
At what age is RAD140 less risky, and is 21 or 23 still too young?
The age at which RAD140 becomes less risky is described, outside the trial record, as nowhere fixed: the ages named run from the end of the teens to the mid-twenties, in some accounts no age makes the compound safe, and three grounds for deferring exposure stand behind that range, that endogenous testosterone should first reach its natural peak, that brain maturation continues into the mid-twenties, and that the hormonal system should finish developing.
Beyond the trial data, the early twenties are therefore still described as an age for deferral, at 21 as at 23, and testosterone replacement therapy, prescribed testosterone that replaces deficient endogenous production, has been described as necessary in one account of exposure in the mid-twenties, at the upper end of that range.
How much does RAD140 lower testosterone in young men, and does it recover?
Outside the published trials, the fall in testosterone on RAD140 in young men is described as marked, and recovery from RAD 140 suppression after exposure ends as uneven, quick in some accounts and slow or incomplete in others; the pattern has been described at sixteen, with constant tiredness and low testosterone persisting for months, and testosterone replacement therapy as necessary in the account from the mid-twenties, despite the drugs administered after exposure ended. Such accounts divide on age, some holding that a younger endocrine system recovers faster and others that a system still developing may not recover at all.
Among the drugs described outside the trials, two are named most often for restarting endogenous production: clomiphene, a selective oestrogen receptor modulator used in fertility medicine, and enclomiphene, its purified trans-isomer. Post-cycle therapy is described, outside the trial record, as the course of these drugs after exposure ends, meant to reverse the suppression of luteinising hormone (LH), the pituitary signal that tells the testes to make testosterone, and so to restore the chain between LH and testosterone.
That suppression is generally held to run through the hypothalamic-pituitary-gonadal axis (the hormonal chain linking the brain and the testes), along which each step leads to the next:
The hypothalamus and pituitary respond to RAD140 as an androgen.
They release less luteinising hormone.
They release less follicle-stimulating hormone.
The testes make less testosterone.
The testes make fewer sperm.
The fall is commonly described as dose-dependent and marked rather than mild, reaching hypogonadotropic hypogonadism, low gonadal output from deficient pituitary signalling, and recovery after exposure ends is understood to be usual but not guaranteed, complete within weeks in some cases and still incomplete many months later in others.
Why the young mice fared worse on RAD140
The study that compared the two ages gave young and adult female mice RAD140 at 5 mg/kg or a control solution for ten weeks, subjected the dorsiflexors to repeated bouts of eccentric contractions (made while skeletal muscle fibres lengthen under load) and measured torque before and after each bout; from those measurements the authors derived adaptive potential (the gain in torque across repeated bouts), and they assessed health span through mortality risk and a frailty index, a score that sums age-related health deficits.
[Figure 1. How the RAD140 mouse study was run. Young and adult female mice received RAD140 at 5 mg/kg or a control solution for ten weeks, with repeated loading of the shin muscles. Frailty and mortality risk rose at both ages; adaptive potential fell only in the young.]
Frailty status and mortality risk rose in both the young and the adult treated groups compared with controls (p ≤ 0.042), adaptive potential fell in the young mice (p = 0.040) but not in the adults (p = 0.688), so the young animals fared worse in their adaptive response to repeated bouts, and after two to three weeks of recovery torque did not differ between groups (p ≥ 0.135). From these results the authors concluded that RAD140 at that dose reduced indices of overall health and failed to improve strength, and that it may be more detrimental than beneficial as a countermeasure to sarcopenia.
The published summary offers no mechanism for the difference between the age groups; the study used female mice only, and a dose given to mice does not translate directly to humans, so the treated arm describes an animal exposure rather than a human dose.
No long-term studies have investigated how RAD140 influences strength in ageing muscle.
The evidence on RAD140 in young men stops at four boundaries. The human record of RAD 140 in a teenager is a single case report, which shows that myopericarditis followed one exposure and gives no measure of its frequency; the finding on cholestatic liver injury comes from a monograph on SARMs as a class, which lists the injury without isolating any age group; the product finding rests on tests in a single country; and the data on young animals come from female mice alone. Together these records point towards harm at a young age without measuring its size. The RAD-140 for sale to laboratories here comes with batch and purity data, so at least the amount behind a measurement is known.
Accounts outside the published studies describe several further effects, erectile dysfunction, loss of libido, tiredness, anxiety, low testosterone after exposure ends and a loss of height, and none of them has been measured in a published study among this article’s sources.
None of the records behind a teenager’s question comes with a measured amount, only a label, and regulators’ tests of SARM products have shown how little a label can be trusted; what makes legit RAD 140 is therefore an analytical question.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What did the 2024 case report describe in a 16-year-old boy after his first use of a product labelled RAD-140?
Inflammation of the heart muscle and the sac around it ✓
Cholestatic injury slowing the flow of bile in the liver
Early closure of the growth plates in the long bones
Lasting loss of his own testosterone production
The case report describes myopericarditis in a 16-year-old boy after his first use of a product labelled RAD-140, a single case that gives no rate.
In the 2023 mouse study, which effect of RAD140 appeared in the young mice but not in the adults?
Lower gain in muscle force across repeated bouts ✓
Higher frailty and mortality risk than in controls
Lower muscle force after weeks of recovery
Greater strength gains than in untreated mice
Frailty and mortality risk rose at both ages, but only the young mice lost adaptive potential, the gain in torque across repeated bouts.
What did Australia's Therapeutic Goods Administration find when it tested unapproved SARM products?
Products held less of the compound than labelled ✓
Products held far more of the compound than labelled
Products held another SARM in place of RAD140
Products matched their labels but were impure
The TGA found that unapproved SARM products on the Australian market held markedly less than their labels stated.
What does the LiverTox database link with SARMs as a class?
Cholestatic liver injury that impairs bile flow ✓
Liver injury seen mainly in men under 21
Fatty liver disease that slowly develops over years
Inflammation of the heart muscle in young men
LiverTox lists cholestatic liver injury for SARMs as a class. The entry is tied to no age group and gives no size of risk.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
RAD 140 teenager: what a case report and animal data show
By Elizabeth Hyams · Reviewed by Matthew Waite, MB BChir
Published · 15 min read
What RAD140 means for teenagers and young men
What the evidence on RAD 140 teenager exposure records is harm, not safety. A published case report describes a 16-year-old boy who developed myopericarditis, inflammation of cardiac muscle and of the sac around the heart, after his first dose, and its authors add that such side effects can be life-threatening and are poorly characterised.
A mouse study adds that ten weeks of the compound raised mortality risk and frailty (a measured accumulation of age-related health deficits) and in the younger animals blunted the adaptation of skeletal muscle to repeated loading. The warnings aimed at the young rest on something else, on effects described only outside the published studies: suppression of testosterone (the principal androgen made by the testes), erectile dysfunction, and possible harm to growth.
What is RAD 140, and what has it been studied for? RAD140 is a selective androgen receptor modulator (SARM) acting on the androgen receptor, the protein inside cells that responds to androgens, and the 2023 mouse study framed vosilasarm as a possible means of delaying sarcopenia, the age-related loss of skeletal muscle mass. This article sets out what is recorded in the case report, in a drug-safety monograph on the SARM class, in an Australian regulator’s product tests and in the mouse study, and then what is described outside the published studies; the compound’s effects in older adults are covered on other pages of the site.
What are the risks of RAD140 for someone under 21, with figures?
Three records of RAD 140 side effects carry the risks of RAD140 under 21: myopericarditis in a teenage boy after his first dose; cholestatic liver injury (drug-induced damage that impairs bile flow) listed for SARMs as a class; and products that hold less of the compound than their labels state.
Few figures attach to them, and the table below gives all there are: from the case report the boy’s age and the single dose before onset, from the mouse study the dose and length of its treated arm, given to young and adult female mice, in which RAD140 worsened the health of both treated age groups and blunted the adaptive response of the young animals.
Each record has a boundary. The case report covers one patient, the liver monograph covers a whole class of compounds rather than any single age group, and taken at their own level the three records show an event that has occurred once, a pattern of injury linked with the class and the limit of what a label can be trusted to state.
LiverTox links SARMs as a class with cholestatic liver injury in a listing tied to no age group, so one question has the same answer at eighteen as at forty, and its own article gives it: Is RAD 140 liver toxic?
Four published records and their limits
Heart inflammation in a boy after his first dose
One dose of a product labelled Testolone (RAD-140) preceded the myopericarditis in the published case on RAD-140 and the heart, and the patient was a boy. Myopericarditis joins inflammation of cardiac muscle to inflammation of the pericardium, the thin fibrous sac enclosing the heart, and the authors set his exposure beside a warning that potentially life-threatening side effects remain poorly characterised in his age group.
The limit of the record follows from its form. A single case shows that myopericarditis occurred after one exposure to a product labelled RAD-140 and not how often the event occurs; the published summary gives no rate, and one case cannot separate the compound from other possible causes, so what the record establishes is an occurrence rather than a frequency. Laboratories that buy UK SARMs from the shop receive the batch data that a label does not give.
What does RAD140 actually do to a teenager’s body, according to evidence?
Beyond the trial data, the effects described for RAD140 in the teenage years are adverse with one exception, an increase in strength.
Erectile dysfunction has been described after a short exposure and, in other accounts, as absent after a longer one, so the duration of exposure alone does not account for the difference, and the effects those accounts describe in the teenage years run as follows:
Most of these accounts concern RAD140 in combination with other compounds, chiefly MK-677 (the growth hormone secretagogue ibutamoren), so the effects they describe cannot be attributed to RAD140 alone; that combination is the first limit of the accounts of RAD140 on Reddit and similar sites, which rarely isolate one compound and so sketch a pattern of suppression and its consequences rather than the effect of any single agent.
Does RAD140 stunt growth or close growth plates in teenagers?
Among the effects described outside the trials, RAD140 may stunt growth and cause early closure of the growth plates, the cartilage zones where long bones lengthen, known in anatomy as epiphyseal plates; only the suppression of endogenous testosterone comes up more often. A still-growing skeleton is accordingly held to be one never to be exposed to the compound, lost height is reported after exposure in the late teens, judged against the family’s greater height and left as an open question, and lifelong incomplete development appears in a few accounts as the cost of exposure before growth has finished.
The opposite possibility is described, outside the trial record, as a widening of the skeletal frame while the growth plates remain open, and the same accounts leave open whether drugs administered after exposure to restart endogenous testosterone production would themselves affect growth; both the stunting and the widening rest on conjecture rather than on measurement.
Closure of the plates is widely understood to be driven by sex hormones, chiefly oestrogen made from testosterone, though androgens also act directly on the cartilage, so early or excess androgen exposure during puberty is held to speed skeletal maturation and close them early, at the cost of final adult height. RAD140 is described as not converting to oestrogen, and the claim that it therefore spares the plates is regarded as speculative, because SARMs suppress endogenous testosterone production and so disturb the hormones governing the pubertal growth spurt, which is why the risk of lost height is considered real.
Does RAD140 affect brain development in teenagers?
RAD140’s effect on brain development in teenagers is generally held to be unknown, because the compound has never been studied in adolescents. The teenage brain is still maturing, testosterone helps to shape that maturation through puberty, and SARMs such as RAD140 suppress endogenous testosterone production, so they are held capable of disturbing the hormonal signals that shape the adolescent brain.
Against that uncertainty, laboratory work in cultured neurons and in rodents has described RAD-140 neuroprotective effects, an early preclinical record that says nothing about safety in the developing brain; the usual view is that a risk to adolescent brain development cannot be ruled out, and that the absence of data gives reason for concern rather than reassurance.
Is it safe to take SARMs like RAD140 at 18?
In descriptions beyond the trials, exposure to SARMs such as RAD140 at eighteen is widely held to be premature rather than safe, and the course most often described is deferral until the hormonal system has settled: at that age endogenous testosterone is already high, so the compound is said to add little in return for what it puts at risk, and the chief long-term danger of early exposure is a lasting loss of endogenous testosterone production.
Uncertainty over what a product actually contains has also been described as a further ground against early exposure, and eighteen as too early whatever the compound, because at that age the endocrine system is held to be still maturing; a minority view accepts exposure only when it is bracketed by RAD 140 blood work, laboratory measurements of circulating hormone levels taken before and after.
Are very low doses of RAD140 any safer at 18?
Beyond the trial data a low dose of RAD140 at eighteen is not described as safe, though a small daily amount over a short period is sometimes described as doing little lasting harm; other accounts set the stage of development against that view and name age rather than amount as the ground for the warning, so the two positions differ in what they hold decisive, one regarding the amount of exposure as the quantity to keep small and the other the maturity of the hormonal system as the deciding condition.
Taken together, in those accounts, the grounds against exposure at eighteen are these:
At what age is RAD140 less risky, and is 21 or 23 still too young?
The age at which RAD140 becomes less risky is described, outside the trial record, as nowhere fixed: the ages named run from the end of the teens to the mid-twenties, in some accounts no age makes the compound safe, and three grounds for deferring exposure stand behind that range, that endogenous testosterone should first reach its natural peak, that brain maturation continues into the mid-twenties, and that the hormonal system should finish developing.
Beyond the trial data, the early twenties are therefore still described as an age for deferral, at 21 as at 23, and testosterone replacement therapy, prescribed testosterone that replaces deficient endogenous production, has been described as necessary in one account of exposure in the mid-twenties, at the upper end of that range.
How much does RAD140 lower testosterone in young men, and does it recover?
Outside the published trials, the fall in testosterone on RAD140 in young men is described as marked, and recovery from RAD 140 suppression after exposure ends as uneven, quick in some accounts and slow or incomplete in others; the pattern has been described at sixteen, with constant tiredness and low testosterone persisting for months, and testosterone replacement therapy as necessary in the account from the mid-twenties, despite the drugs administered after exposure ended. Such accounts divide on age, some holding that a younger endocrine system recovers faster and others that a system still developing may not recover at all.
Among the drugs described outside the trials, two are named most often for restarting endogenous production: clomiphene, a selective oestrogen receptor modulator used in fertility medicine, and enclomiphene, its purified trans-isomer. Post-cycle therapy is described, outside the trial record, as the course of these drugs after exposure ends, meant to reverse the suppression of luteinising hormone (LH), the pituitary signal that tells the testes to make testosterone, and so to restore the chain between LH and testosterone.
That suppression is generally held to run through the hypothalamic-pituitary-gonadal axis (the hormonal chain linking the brain and the testes), along which each step leads to the next:
The fall is commonly described as dose-dependent and marked rather than mild, reaching hypogonadotropic hypogonadism, low gonadal output from deficient pituitary signalling, and recovery after exposure ends is understood to be usual but not guaranteed, complete within weeks in some cases and still incomplete many months later in others.
Why the young mice fared worse on RAD140
The study that compared the two ages gave young and adult female mice RAD140 at 5 mg/kg or a control solution for ten weeks, subjected the dorsiflexors to repeated bouts of eccentric contractions (made while skeletal muscle fibres lengthen under load) and measured torque before and after each bout; from those measurements the authors derived adaptive potential (the gain in torque across repeated bouts), and they assessed health span through mortality risk and a frailty index, a score that sums age-related health deficits.
Frailty status and mortality risk rose in both the young and the adult treated groups compared with controls (p ≤ 0.042), adaptive potential fell in the young mice (p = 0.040) but not in the adults (p = 0.688), so the young animals fared worse in their adaptive response to repeated bouts, and after two to three weeks of recovery torque did not differ between groups (p ≥ 0.135). From these results the authors concluded that RAD140 at that dose reduced indices of overall health and failed to improve strength, and that it may be more detrimental than beneficial as a countermeasure to sarcopenia.
The published summary offers no mechanism for the difference between the age groups; the study used female mice only, and a dose given to mice does not translate directly to humans, so the treated arm describes an animal exposure rather than a human dose.
Limits of the evidence on RAD140 in young men
The evidence on RAD140 in young men stops at four boundaries. The human record of RAD 140 in a teenager is a single case report, which shows that myopericarditis followed one exposure and gives no measure of its frequency; the finding on cholestatic liver injury comes from a monograph on SARMs as a class, which lists the injury without isolating any age group; the product finding rests on tests in a single country; and the data on young animals come from female mice alone. Together these records point towards harm at a young age without measuring its size. The RAD-140 for sale to laboratories here comes with batch and purity data, so at least the amount behind a measurement is known.
Accounts outside the published studies describe several further effects, erectile dysfunction, loss of libido, tiredness, anxiety, low testosterone after exposure ends and a loss of height, and none of them has been measured in a published study among this article’s sources.
None of the records behind a teenager’s question comes with a measured amount, only a label, and regulators’ tests of SARM products have shown how little a label can be trusted; what makes legit RAD 140 is therefore an analytical question.
Check what you remember
4 questions on this article; the right answer is marked.
The case report describes myopericarditis in a 16-year-old boy after his first use of a product labelled RAD-140, a single case that gives no rate.
Frailty and mortality risk rose at both ages, but only the young mice lost adaptive potential, the gain in torque across repeated bouts.
The TGA found that unapproved SARM products on the Australian market held markedly less than their labels stated.
LiverTox lists cholestatic liver injury for SARMs as a class. The entry is tied to no age group and gives no size of risk.
Elizabeth Hyams · Imperial College London
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Matthew Waite, MB BChir · Imperial College Healthcare · Last reviewed
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Related Posts
Is RAD-140 bad for kidneys? What the case reports show
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
Is RAD140 liver toxic? What trials and case reports show
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
Does RAD 140 increase libido? Erections and the evidence
Does RAD 140 increase libido: accounts describe an early rise then a fall, and a case report links RAD140 supplements to suppressed testosterone.
How bad is RAD-140 for the heart? What the evidence shows
How bad is RAD-140 for the heart remains unmeasured in published studies, while case reports describe myocarditis and heart failure after exposure.